235 related articles for article (PubMed ID: 26303343)
1. Plerixafor (Mozobil): A Stem Cell-Mobilizing Agent for Transplantation in Lymphoma Patients Predicted to Be Poor Mobilizers - A Pilot Study.
Danylesko I; Sareli R; Varda-Bloom N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
Acta Haematol; 2016; 135(1):29-36. PubMed ID: 26303343
[TBL] [Abstract][Full Text] [Related]
2. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience.
Basak GW; Knopinska-Posluszny W; Matuszak M; Kisiel E; Hawrylecka D; Szmigielska-Kaplon A; Urbaniak-Kujda D; Dybko J; Zielinska P; Dabrowska-Iwanicka A; Werkun J; Rzepecki P; Wroblewska W; Wiktor-Jedrzejczak W
Ann Hematol; 2011 May; 90(5):557-68. PubMed ID: 20938660
[TBL] [Abstract][Full Text] [Related]
4. European data on stem cell mobilization with plerixafor in non-Hodgkin's lymphoma, Hodgkin's lymphoma and multiple myeloma patients. A subgroup analysis of the European Consortium of stem cell mobilization.
Hübel K; Fresen MM; Apperley JF; Basak GW; Douglas KW; Gabriel IH; Geraldes C; Jaksic O; Koristek Z; Kröger N; Lanza F; Lemoli RM; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF
Bone Marrow Transplant; 2012 Aug; 47(8):1046-50. PubMed ID: 22080971
[TBL] [Abstract][Full Text] [Related]
5. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.
Shaughnessy P; Uberti J; Devine S; Maziarz RT; Vose J; Micallef I; Jacobsen E; McCarty J; Stiff P; Artz A; Ball ED; Berryman R; Dugan M; Joyce R; Hsu FJ; Johns D; McSweeney P
Bone Marrow Transplant; 2013 Jun; 48(6):777-81. PubMed ID: 23178544
[TBL] [Abstract][Full Text] [Related]
6. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
[TBL] [Abstract][Full Text] [Related]
8. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
Attolico I; Pavone V; Ostuni A; Rossini B; Musso M; Crescimanno A; Martino M; Iacopino P; Milone G; Tedeschi P; Coluzzi S; Nuccorini R; Pascale S; Di Nardo E; Olivieri A
Biol Blood Marrow Transplant; 2012 Feb; 18(2):241-9. PubMed ID: 21791194
[TBL] [Abstract][Full Text] [Related]
9. Plerixafor in poor stem cell mobilizers: the Belgian Compassionate Use Program.
Selleslag D; Dierickx D; Breems DA; Huynh P; Van De Velde A; Meers S; Brouwer E; Mertens A
Acta Clin Belg; 2011; 66(3):200-4. PubMed ID: 21837928
[TBL] [Abstract][Full Text] [Related]
10. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition.
Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
Transfus Apher Sci; 2012 Jun; 46(3):257-62. PubMed ID: 22465758
[TBL] [Abstract][Full Text] [Related]
11. Who should be really considered as a poor mobilizer in the plerixafor era?
Andreola G; Vanazzi A; Radice D; Babic A; Rabascio C; Negri M; Martinelli G; Laszlo D
Transfus Apher Sci; 2012 Aug; 47(1):27-32. PubMed ID: 22480954
[TBL] [Abstract][Full Text] [Related]
12. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
Hübel K; Fresen MM; Salwender H; Basara N; Beier R; Theurich S; Christopeit M; Bogner C; Galm O; Hartwig R; Heits F; Lordick F; Rösler W; Wehler D; Zander AR; Albert MH; Dressler S; Ebinger M; Frickhofen N; Hertenstein B; Kiehl M; Liebler S; von Lilienfeld-Toal M; Weidmann E; Weigelt C; Lange F; Kröger N
Bone Marrow Transplant; 2011 Aug; 46(8):1045-52. PubMed ID: 20972470
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation.
Stover JT; Shaw JR; Kuchibhatla M; Horwitz ME; Engemann AM
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1290-1294. PubMed ID: 28411174
[TBL] [Abstract][Full Text] [Related]
14. Plerixafor for mobilization and collection of haematopoietic stem cells for autologous transplantation in Japanese patients with non-Hodgkin lymphoma: a randomized phase 2 study.
Matsue K; Kumagai K; Sugiura I; Ishikawa T; Igarashi T; Sato T; Uchiyama M; Miyamoto T; Ono T; Ueda Y; Kiguchi T; Sunaga Y; Sasaki T; Suzuki K
Int J Hematol; 2018 Nov; 108(5):524-534. PubMed ID: 30043330
[TBL] [Abstract][Full Text] [Related]
15. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.
Cheng J; Schmitt M; Wuchter P; Buss EC; Witzens-Harig M; Neben K; Hundemer M; Hillengass J; Alexi R; Goldschmidt H; Chen BA; Ho AD; Schmitt A
Transfusion; 2015 Feb; 55(2):275-83. PubMed ID: 25117969
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
Jantunen E; Kuittinen T; Mahlamäki E; Pyörälä M; Mäntymaa P; Nousiainen T
Eur J Haematol; 2011 Apr; 86(4):299-304. PubMed ID: 21198864
[TBL] [Abstract][Full Text] [Related]
17. Use of plerixafor for peripheral blood stem cell mobilization failure in children.
Emir S; Demir HA; Aksu T; Kara A; Özgüner M; Tunç B
Transfus Apher Sci; 2014 Apr; 50(2):214-8. PubMed ID: 24512717
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
Stewart DA; Smith C; MacFarland R; Calandra G
Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
[TBL] [Abstract][Full Text] [Related]
19. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
Keating GM
Drugs; 2011 Aug; 71(12):1623-47. PubMed ID: 21861545
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Malard F; Kröger N; Gabriel IH; Hübel K; Apperley JF; Basak GW; Douglas KW; Geraldes C; Jaksic O; Koristek Z; Lanza F; Lemoli R; Mikala G; Selleslag D; Worel N; Mohty M; Duarte RF
Biol Blood Marrow Transplant; 2012 Feb; 18(2):314-7. PubMed ID: 22001752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
